About SAMIN DAROU

Samin Darou Iranian Company (Joint Stock) was registered in December 2014 and after equipping the factory with facilities and equipment and creating the necessary spaces for the production of Active Pharmaceutical Ingredients in accordance with GMP principles, it was put into operation in October 2018. The factory was built on a land area of 7000 square meters and with an infrastructure of 3400 square meters in Kaveh Industrial City. The company has produced 17 Active Pharmaceutical Ingredients including Metformin hydrochloride, Azithromycin, Thiamine hydrochloride, Pantoprazole Sodium, Clarithromycin, Celecoxib, Methocarbamol, Losartan, Gabapentin, Fexofenadine, Biperiden hydrochloride, Atorvastatin, Hydroxychloroquine, Niacin, Famotidine, Acyclovir, and Venlafaxine. In the second half of 2019, a pellet products unit was designed and constructed, producing 5 pharmaceutical products including Tamsulosin 0.2%, Pantoprazole Sodium 15%, Diclofenac Sodium 45%, Esomeprazole Magnesium 22.5%, and Omeprazole 8.5%.

Services (9)

• API (Active Pharmaceutical Ingredient)
• Tamsulosin 0.2%
• Esomeprazole Magnesium 22.5%
• Omeprazole 8.5%
• Tamsulosin 0.2% Pellet
• Omeprazole 8.5% Pellet
• Tamsulosin HCl Sustained Release Pellets 0.2%
• Esomeprazole Magnesium Delayed Release Pellets 22.5%
• Omeprazole Delayed Release Pellets 8.5%